Actavis
Allergan

After seven months of resisting a takeover bid from Canada's Valeant Pharmaceuticals International, Allergan Inc. agreed on Nov. 17 to be acquired by Irish generic drug maker Actavis plc in a cash and stock deal valued at $66 billion. It was the largest M&A deal announced to date in 2014.

Cleary Gottlieb Steen & Hamilton and Weil, Gotshal & Manges are advising Actavis, while Latham & Watkins and Wachtell, Lipton, Rosen & Katz are representing Irvine, Calif.-based Allergan.

At Cleary Gottlieb, M&A partners Victor Lewkow and Paul Shim are leading a team that includes debt finance partner Meme Peponis, capital markets partner Jeffrey Karpf, employee benefits partner Michael Albano, tax partner Jason Factor, litigation partners Mitchell Lowenthal and Roger Cooper, antitrust partner Nicholas Levy and counsel Christopher Cook and partner-elect James Langston.